Similar expression profiles in CD34(+) cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib

The life expectancy of patients with chronic phase chronic myeloid leukemia on tyrosine kinase inhibitor therapy now approaches that of the general population. Approximately 60% of patients treated with second generation tyrosine kinase inhibitors achieve a deep molecular response, the prerequisite...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Ami B., Lange, Thoralf, Pomicter, Anthony D., Conley, Christopher J., Harrington, Christina A., Reynolds, Kimberly R., Kelley, Todd W., O’Hare, Thomas, Deininger, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915162/
https://www.ncbi.nlm.nih.gov/pubmed/29707154
http://dx.doi.org/10.18632/oncotarget.24954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915162/
https://www.ncbi.nlm.nih.gov/pubmed/29707154
http://dx.doi.org/10.18632/oncotarget.24954

Ejemplares similares